Cargando…

Assessment of Sleep in Children with Mucopolysaccharidosis Type III

Sleep disturbances are prevalent in mucopolysaccharidosis Type III (MPS III), yet there is a lack of objective, ecologically valid evidence detailing sleep quantity, quality or circadian system. Eight children with MPS III and eight age-matched typically developing children wore an actigraph for 7–1...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mahon, Louise Victoria, Lomax, Michelle, Grant, Sheena, Cross, Elaine, Hare, Dougal Julian, Wraith, James Ed, Jones, Simon, Bigger, Brian, Langford-Smith, Kia, Canal, Maria
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2014
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3913580/ https://www.ncbi.nlm.nih.gov/pubmed/24504123 http://dx.doi.org/10.1371/journal.pone.0084128

Ejemplares similares

An investigation of the middle and late behavioural phenotypes of Mucopolysaccharidosis Type-III
por: Cross, Elaine M, et al.
Publicado: (2014)

Actigraphic investigation of circadian rhythm functioning and activity levels in children with mucopolysaccharidosis type III (Sanfilippo syndrome)
por: Mumford, Rachel A., et al.
Publicado: (2015)

Female Mucopolysaccharidosis IIIA Mice Exhibit Hyperactivity and a Reduced Sense of Danger in the Open Field Test
por: Langford-Smith, Alex, et al.
Publicado: (2011)

Neuropathology in Mouse Models of Mucopolysaccharidosis Type I, IIIA and IIIB
por: Wilkinson, Fiona L., et al.
Publicado: (2012)

Heparan Sulfate Inhibits Hematopoietic Stem and Progenitor Cell Migration and Engraftment in Mucopolysaccharidosis I
por: Watson, H. Angharad, et al.
Publicado: (2014)

Recommendations on clinical trial design for treatment of Mucopolysaccharidosis Type III
por: Ghosh, Arunabha, et al.
Publicado: (2017)

Signal One and Two Blockade Are Both Critical for Non-Myeloablative Murine HSCT across a Major Histocompatibility Complex Barrier
por: Langford-Smith, Kia J., et al.
Publicado: (2013)

The prevalence of and survival in Mucopolysaccharidosis I: Hurler, Hurler-Scheie and Scheie syndromes in the UK
por: Moore, David, et al.
Publicado: (2008)

Novel therapies for mucopolysaccharidosis type III
por: Seker Yilmaz, Berna, et al.
Publicado: (2020)

Sleep-related hypermotor epilepsy in a patient with mucopolysaccharidosis type III
por: Abramova, Anna A., et al.
Publicado: (2021)

Heparin cofactor II-thrombin complex and dermatan sulphate:chondroitin sulphate ratio are biomarkers of short- and long-term treatment effects in mucopolysaccharide diseases
por: Langford-Smith, Kia Jane, et al.
Publicado: (2010)

Respiratory and sleep disorders in mucopolysaccharidosis
por: Berger, Kenneth I., et al.
Publicado: (2012)

Effects of enzyme replacement therapy on growth in patients with mucopolysaccharidosis type II
por: Schulze-Frenking, G., et al.
Publicado: (2010)

Hip pathologies in mucopolysaccharidosis type III
por: Breyer, Sandra Rafaela, et al.
Publicado: (2021)

Mucopolysaccharidosis III: Molecular basis and treatment
por: Spahiu, Lidvana, et al.
Publicado: (2021)

Airway-Related Symptoms and Surgeries in Patients With Mucopolysaccharidosis I
por: Arn, Pamela, et al.
Publicado: (2015)

Genistein Improves Neuropathology and Corrects Behaviour in a Mouse Model of Neurodegenerative Metabolic Disease
por: Malinowska, Marcelina, et al.
Publicado: (2010)

Current and Future Treatment of Mucopolysaccharidosis (MPS) Type II: Is Brain-Targeted Stem Cell Gene Therapy the Solution for This Devastating Disorder?
por: Horgan, Claire, et al.
Publicado: (2022)

Strategies for the Induction of Immune Tolerance to Enzyme Replacement Therapy in Mucopolysaccharidosis Type I
por: Ghosh, Arunabha, et al.
Publicado: (2019)

Sleep disordered breathing in mucopolysaccharidosis I: a multivariate analysis of patient, therapeutic and metabolic correlators modifying long term clinical outcome
por: Pal, Abhijit Ricky, et al.
Publicado: (2015)

Substrate accumulation and extracellular matrix remodelling promote persistent upper airway disease in mucopolysaccharidosis patients on enzyme replacement therapy
por: Pal, Abhijit Ricky, et al.
Publicado: (2018)

Orthopedic manifestations in patients with mucopolysaccharidosis type II (Hunter syndrome) enrolled in the Hunter Outcome Survey
por: Link, Bianca, et al.
Publicado: (2010)

RETRACTED: An Innovative Tool for Evidence-Based, Personalized Treatment Trials in Mucopolysaccharidosis
por: Wiesinger, Anna-Maria, et al.
Publicado: (2023)

Identification of age-dependent motor and neuropsychological behavioural abnormalities in a mouse model of Mucopolysaccharidosis Type II
por: Gleitz, Hélène F. E., et al.
Publicado: (2017)

Cognitive development in patients with Mucopolysaccharidosis type III (Sanfilippo syndrome)
por: Valstar, Marlies J, et al.
Publicado: (2011)

Cardiac characteristics and natural progression in Taiwanese patients with mucopolysaccharidosis III
por: Lin, Hsiang-Yu, et al.
Publicado: (2019)

Growth charts for patients with Sanfilippo syndrome (Mucopolysaccharidosis type III)
por: Muschol, Nicole M., et al.
Publicado: (2019)

Intraparenchymal convection enhanced delivery of AAV in sheep to treat Mucopolysaccharidosis IIIC
por: O’Leary, Claire, et al.
Publicado: (2023)

Protein Misfolding as an Underlying Molecular Defect in Mucopolysaccharidosis III Type C
por: Feldhammer, Matthew, et al.
Publicado: (2009)

Gastrointestinal Manifestations in Mucopolysaccharidosis Type III: Review of Death Certificates and the Literature
por: Thomas, Sophie, et al.
Publicado: (2021)

Natural History and Molecular Characteristics of Korean Patients with Mucopolysaccharidosis Type III
por: Kim, Min-Sun, et al.
Publicado: (2022)

Myeloid/Microglial Driven Autologous Hematopoietic Stem Cell Gene Therapy Corrects a Neuronopathic Lysosomal Disease
por: Sergijenko, Ana, et al.
Publicado: (2013)

Mucopolysaccharidosis VI
por: Valayannopoulos, Vassili, et al.
Publicado: (2010)

Early defects in mucopolysaccharidosis type IIIC disrupt excitatory synaptic transmission
por: Pará, Camila, et al.
Publicado: (2021)

Abstract for E- poster Mucopolysaccharidosis III (Sanfilippo Syndrome) with severe behavioural problems
Publicado: (2022)

Neurological, neurobehavioral, and radiological alterations in patients with mucopolysaccharidosis III (Sanfilippo's syndrome) in Brazil
por: do Valle, Daniel Almeida, et al.
Publicado: (2022)

Orofacial abnormalities in mucopolysaccharidosis and mucolipidosis type II and III: A systematic review
por: de Bode, Chiel J., et al.
Publicado: (2022)

Haematopoietic stem cell gene therapy with IL‐1Ra rescues cognitive loss in mucopolysaccharidosis IIIA
por: Parker, Helen, et al.
Publicado: (2020)

Anaesthesia and airway management in mucopolysaccharidosis
por: Walker, Robert, et al.
Publicado: (2012)

Airway Abnormalities in Adult Mucopolysaccharidosis and Development of Salford Mucopolysaccharidosis Airway Score
por: Gadepalli, Chaitanya, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_4935p92tpjp47v3s7aivr25f75